| Literature DB >> 12547005 |
Petra Burgstaller1, Anne Girod, Michael Blind.
Abstract
The increasing number of potential drug target candidates has driven the development of novel technologies designed to identify functionally important targets and enhance the subsequent lead discovery process. Highly specific synthetic nucleic acid ligands--also known as aptamers--offer a new exciting route in the drug discovery process by linking target validation directly with HTS. Recently, aptamers have proven to be valuable tools for modulating the function of endogenous cellular proteins in their natural environment. A set of technologies has been developed to use these sophisticated ligands for the validation of potential drug targets in disease models. Moreover, aptamers that are specific antagonists of protein function can act as substitute interaction partners in HTS assays to facilitate the identification of small-molecule lead compounds.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12547005 DOI: 10.1016/s1359-6446(02)02522-9
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851